Enliven Therapeutics Executives and Directors Sell Hundreds of Thousands of Shares Amidst Surge in Stock Price with Planned 10b5-1 Transactions
Enliven Therapeutics, Inc. (NASDAQ: ELVN) disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on January 13 that several of its senior executives and directors sold company stock under pre-established Rule 10b5-1 trading plans. Between January 8 and 9, Chief Scientific Officer Joseph P. Lyssikatos, as trustee of the Lyssikatos Revocable Trust dated December 15, 2011, sold 132,500 shares of common stock in four open-market transactions, generating approximately $3.25 million in proceeds. The weighted average sale price ranged from about $20.13 to $29.13 per share. As a result, the trust’s indirect holdings declined from approximately 897,688 shares to 765,188 shares, though the filing emphasized that Lyssikatos continues to maintain a substantial stake.
On January 9, Chief Operating Officer Anish Patel, as trustee of the Patel/Dong Family Trust, sold 48,300 shares in two transactions for combined proceeds of about $1.35 million, at weighted average prices of $27.98 and $28.50 per share. Following these transactions, Patel still holds 215,011 shares indirectly through the family trust. During the same period, director Richard A. Heyman, through entities and trusts for which he serves as managing member or trustee, sold a total of 13,920 shares in three transactions at roughly $25 per share, realizing about $348,000 in proceeds. Heyman continues to hold 123,673 shares directly, plus additional indirect holdings, reflecting only modest adjustments under his trading plan.
Enliven Therapeutics is a clinical-stage biotechnology company based in Boulder, Colorado, focused on developing small-molecule precision oncology therapies. Its lead candidate, ELVN-001, is a highly selective active-site tyrosine kinase inhibitor (TKI) targeting the BCR::ABL fusion oncoprotein—the primary driver of chronic myeloid leukemia (CML). ELVN-001 is currently being evaluated in the ENABLE Phase 1/1b trial in patients with relapsed, refractory or intolerant CML and has generated encouraging initial data. In its third-quarter fiscal 2025 results, the company reported a near debt-free balance sheet and approximately $478 million in cash and cash equivalents, providing a cash runway through mid-2029 to support clinical development and operations. Enliven’s mid-term roadmap calls for completing enrollment of the Phase 1b randomized cohort in 2025 and initiating a global Phase 3 pivot trial for ELVN-001 in 2026.
Recently, Enliven has accelerated both pipeline advancement and governance restructuring as it transitions into the late-stage clinical and commercialization phase. On January 8, the company announced a 24-week cumulative major molecular response (MMR) rate of 69% in the ENABLE Phase 1b CML study and reaffirmed its plan to launch the Phase 3 program in the second half of 2026. In parallel, on January 7, Enliven added Scott Garland—who brings over 30 years of oncology and hematology commercialization experience—to its board of directors and accepted the resignation of long-serving director Dr. Andrew Phillips, effecting a board refresh. Bolstered by these technical and governance catalysts, Enliven’s stock reached a 52-week high of $25.64 on January 9, lifting its market capitalization to approximately $1.51 billion. The shares have gained over 49% in the past week. Investors view the recently disclosed 10b5-1 insider sales as partial disposals to secure liquidity and diversify portfolios, while core clinical strategies and governance initiatives remain firmly on track.